Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03015402 · ClinicalTrials.gov registry record · Phase 2

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

A Phase 2 study of Heart Failure and Pulmonary Hypertension Secondary, sponsored by University of Pittsburgh.

Completed
Registry status
Phase 2
Development phase
33
Enrollment target
1
Study location

NCT03015402 is a Phase 2 study of Heart Failure and Pulmonary Hypertension Secondary that has completed, run by University of Pittsburgh. The registered enrollment target is 33 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03015402, a Phase 2 study of Heart Failure and Pulmonary Hypertension Secondary, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
Phase 2
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The main objective of this study is to determine the clinical efficacy of oral inorganic nitrite verses placebo and the therapeutic response with regards to exercise tolerance in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).

Interventions

  • DRUG Placebo Oral Capsule
  • DRUG Sodium Nitrite

Study Locations (1)

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2017-10-30
Est. Completion 2023-01-25
Phase Phase 2

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT03015402

The ClinicalTrials.gov registry entry for NCT03015402 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Capsule is the first listed.

NCT03015402 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03015402 about?

NCT03015402 is a clinical study titled "Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction". The main objective of this study is to determine the clinical efficacy of oral inorganic nitrite verses placebo and the therapeutic response with regards to exercise tolerance in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).

What is the current status of trial NCT03015402?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2017-10-30. Estimated completion is 2023-01-25.

What conditions does trial NCT03015402 study?

This clinical trial studies the following conditions: Heart Failure, Pulmonary Hypertension Secondary.

What interventions are being tested in trial NCT03015402?

The interventions under investigation include: Placebo Oral Capsule (DRUG), Sodium Nitrite (DRUG).

Who is sponsoring clinical trial NCT03015402?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03015402 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.